MP-424 + interferon beta + ribavirin

This is a **combination investigational therapy** consisting of MP-424 (an oral HCV NS3/4A protease inhibitor), interferon beta (a type I interferon with antiviral and immunomodulatory properties), and ribavirin (a nucleoside analog antiviral). The main mechanism is the synergistic antiviral effect against chronic hepatitis C virus (HCV) infection, targeting multiple steps of the viral lifecycle: MP-424 inhibits viral protease activity, interferon beta induces antiviral responses via interferon-stimulated genes, and ribavirin suppresses viral replication through multiple mechanisms. The combination has primarily been investigated for its efficacy and safety in treating chronic hepatitis C, especially in patients unresponsive to previous treatments.